Literature DB >> 2206939

Chemotherapy for advanced bladder cancer: 'Midsummer Night's Dream' or 'Much Ado About Nothing'?

D Raghavan1.   

Abstract

Entities:  

Mesh：

Year:  1990        PMID： 2206939      PMCID： PMC1971441          DOI： 10.1038/bjc.1990.293

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  32 in total

1.  The chemotherapy of urologic cancer.

Authors:  S K Carter; T H Wasserman
Journal:  Cancer       Date:  1975-08       Impact factor: 6.860

2.  Chemotherapy of human solid tumors with 5-fluorouracil.

Authors:  W L WILSON
Journal:  Cancer       Date:  1960 Nov-Dec       Impact factor: 6.860

3.  A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract.

Authors:  B L Hillcoat; D Raghavan; J Matthews; R Kefford; K Yuen; R Woods; I Olver; J Bishop; B Pearson; G Coorey
Journal:  J Clin Oncol       Date:  1989-06       Impact factor: 44.544

4.  Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.

Authors:  C N Sternberg; A Yagoda; H I Scher; R C Watson; N Geller; H W Herr; M J Morse; P C Sogani; E D Vaughan; N Bander
Journal:  Cancer       Date:  1989-12-15       Impact factor: 6.860

Review 5.  Biology and management of bladder cancer.

Authors:  D Raghavan; W U Shipley; M B Garnick; P J Russell; J P Richie
Journal:  N Engl J Med       Date:  1990-04-19       Impact factor: 91.245

6.  Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis.

Authors:  M K Gospodarowicz; N V Hawkins; G A Rawlings; J G Connolly; M A Jewett; G M Thomas; J G Herman; P G Garrett; T Chua; W Duncan
Journal:  J Urol       Date:  1989-12       Impact factor: 7.450

7.  Neo-adjuvant chemotherapy for invasive bladder cancer. Experience with the M-VAC regimen.

Authors:  H Scher; H Herr; C Sternberg; W Fair; G Bosl; M Morse; P Sogani; R Watson; D Dershaw; V Reuter
Journal:  Br J Urol       Date:  1989-09

8.  Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: cause for concern.

Authors:  J P Connor; C A Olsson; M C Benson; F Rapoport; I S Sawczuk
Journal:  Urology       Date:  1989-12       Impact factor: 2.649

9.  A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A National Bladder Cancer Collaborative Group A Study.

Authors:  M S Soloway; A Einstein; M P Corder; W Bonney; G R Prout; J Coombs
Journal:  Cancer       Date:  1983-09-01       Impact factor: 6.860

10.  Clonal analysis of a bladder cancer cell line: an experimental model of tumour heterogeneity.

Authors:  J L Brown; P J Russell; J Philips; J Wotherspoon; D Raghavan
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640
View more
  1 in total

Review 1.  Evaluating prognostic factors: implications for measurement of health care outcome.

Authors:  M C Gulliford
Journal:  J Epidemiol Community Health       Date:  1992-08       Impact factor: 3.710
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.